Boehringer Ingelheim And Zhejiang Hisoar Pharmaceutical Sign Production Alliance
This article was originally published in PharmAsia News
Boehringer Ingelheim and Zhejiang Hisoar Pharmaceutical have signed a strategic production alliance. Under the agreement, Hisoar will invest in a specialized workshop at its new plant in Chuannan and is scheduled to manufacture contract products for BI from 2009. The latter on its part will provide expertise and technology support for Hisoar. Listed on the Shenzhen bourse in 2006, Hisoar specializes in producing and selling pharmaceutical chemicals, active pharmaceutical ingredients and generic drugs. It has established GMP and EHS systems according to international standards. The firm said that the BI collaboration will boost its market position and influence, as well as give it a major leg-up toward globalization
You may also be interested in...
Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.
The US FDA tells manufacturers in two recent warning letters to get to the root cause of contamination problems and take a more proactive approach to cleaning and equipment maintenance.
Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar
On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.